論文

査読有り
2014年3月

Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide

MEDICAL MOLECULAR MORPHOLOGY
  • Akira Matsuno
  • ,
  • Mineko Murakami
  • ,
  • Katsumi Hoya
  • ,
  • Shoko M. Yamada
  • ,
  • Shinya Miyamoto
  • ,
  • So Yamada
  • ,
  • Jae-Hyun Son
  • ,
  • Hajime Nishido
  • ,
  • Fuyuaki Ide
  • ,
  • Hiroshi Nagashima
  • ,
  • Mutsumi Sugaya
  • ,
  • Toshio Hirohata
  • ,
  • Akiko Mizutani
  • ,
  • Hiroko Okinaga
  • ,
  • Yudo Ishii
  • ,
  • Shigeyuki Tahara
  • ,
  • Akira Teramoto
  • ,
  • R. Yoshiyuki Osamura

47
1
開始ページ
1
終了ページ
7
記述言語
英語
掲載種別
DOI
10.1007/s00795-013-0050-z
出版者・発行元
SPRINGER JAPAN KK

There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas. O-6-methyl-guanine-DNA methyltransferase is not the sole molecule determining the sensitivity to TMZ in pituitary carcinomas and atypical adenomas. The Japan Society of Hypothalamic and Pituitary Tumors study suggests that MSH6, one of mismatch repair pathway enzyme, fulfills a contributory role to the efficacy of TMZ treatment for pituitary carcinomas and atypical adenomas. The preserved MSH6 function might be essential for the responsiveness to TMZ treatment in pituitary carcinomas and atypical adenomas.

Web of Science ® 被引用回数 : 16

リンク情報
DOI
https://doi.org/10.1007/s00795-013-0050-z
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/23955641
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000335514600001&DestApp=WOS_CPL

エクスポート
BibTeX RIS